These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 16804994)
21. Overcoming the Next Barriers to Successful Therapy. Cohen IJ; Baris H; Mistry PK; Sands MS Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():629. PubMed ID: 27491209 [No Abstract] [Full Text] [Related]
22. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease. Morel CF; Clarke JT Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525 [TBL] [Abstract][Full Text] [Related]
23. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases. Sánchez-Fernández EM; García Fernández JM; Mellet CO Chem Commun (Camb); 2016 Apr; 52(32):5497-515. PubMed ID: 27043200 [TBL] [Abstract][Full Text] [Related]
24. Protein structural features predict responsiveness to pharmacological chaperone treatment for three lysosomal storage disorders. Woodard J; Zheng W; Zhang Y PLoS Comput Biol; 2021 Sep; 17(9):e1009370. PubMed ID: 34529671 [TBL] [Abstract][Full Text] [Related]
25. Gaucher and Fabry diseases: from understanding pathophysiology to rational therapies. Brady RO Acta Paediatr Suppl; 2003 Dec; 92(443):19-24. PubMed ID: 14989461 [TBL] [Abstract][Full Text] [Related]
26. [Treatment of Gaucher disease: enzyme replacement therapy and emerging therapies (chemical chaperone and gene therapy)]. Grosbois B; Revest M; Decaux O; Sebillot M Ann Biol Clin (Paris); 2006; 64(6):600-2. PubMed ID: 17256241 [No Abstract] [Full Text] [Related]
27. [Gene therapy of Gaucher's and Fabry's diseases: current status and prospects]. Fabrega S; Lehn P J Soc Biol; 2002; 196(2):175-81. PubMed ID: 12360746 [TBL] [Abstract][Full Text] [Related]
36. Fabry disease: kidney transplantation as an enzyme replacement technic. Philippart M Birth Defects Orig Artic Ser; 1973 Mar; 9(2):81-7. PubMed ID: 4215478 [No Abstract] [Full Text] [Related]
37. Enzyme replacement therapy for Fabry disease: proving the clinical benefit. Breunig F; Wanner C Nephrol Dial Transplant; 2003 Jan; 18(1):7-9. PubMed ID: 12480950 [No Abstract] [Full Text] [Related]
38. The role of neurogenetics in Gaucher disease. Brady RO; Barton NW; Grabowski GA Arch Neurol; 1993 Nov; 50(11):1212-24. PubMed ID: 8215980 [TBL] [Abstract][Full Text] [Related]
39. Novel therapeutic targets for the treatment of Fabry disease. Hollak CE; Vedder AC; Linthorst GE; Aerts JM Expert Opin Ther Targets; 2007 Jun; 11(6):821-33. PubMed ID: 17504019 [TBL] [Abstract][Full Text] [Related]
40. The role of antibodies in enzyme treatments and therapeutic strategies. Bigger BW; Saif M; Linthorst GE Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):183-94. PubMed ID: 25987172 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]